Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard-of-Care Regimen for Previously Unmanaged CLL
The MRD-guided treatment approach has a significant advantage over chemotherapy.
Source: pharmacytimes.com
Peter Hillmen News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Peter Hillmen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Peter Hillmen Today - Breaking & Trending Today
-Medtech_THAI_STUDIO_LAB_249_5668a625a9ad46978c78f22fdb7af040-620x480.jpg)
Personalized treatment for leukemia results in longer life and fewer side effects
Personalized treatment for the most common form of adult leukemia helps patients survive for longer and stay in remission, a phase III trial has found.
Source: news-medical.net
Measurable Residual Disease-Guided Therapy Promising in CLL
The ibrutinib-venetoclax combination was particularly effective in patients with chronic lymphocytic leukemia with high-risk features such as IGHV unmutated disease or chromosomal abnormalities.
Source: medscape.com
'New Gold Standard' for Previously Untreated CLL
Personalized, time-limited regimen of venetoclax plus ibrutinib improves survival versus FCR
Source: medpagetoday.com
Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard of Care Regimen for Previously Untreated CLL
This is the first trial to show that a MRD-guided approach with treatment beyond MRD negativity has a significant advantage over chemotherapy, both in terms of PFS and OS.
Source: pharmacytimes.com